

corrected, the supplemental reissue declaration under 37 CFR 1.175(b)(1) need not specifically identify any other error or errors being corrected.


Since the filing of this reissue application, and in connection with a merger with another company, the name of the original reissue applicant, Chiron Corporation, has been changed to Novartis Vaccines and Diagnostics, Inc. The document evidencing this merger and name change is recorded at reel 018044, frame 0246. A submission under 37 CFR 3.73(b) establishing the assignee's right to take action in this reissue application accompanies this response.

Conclusion

Applicant believes that all pending claims are allowable and respectfully requests a Notice of Allowance for this application from the Examiner. Should the Examiner believe that a telephone conference would expedite the prosecution of this application, the undersigned can be reached at (510) 663-1100. If any further fees are due in connection with the filing of this amendment, the Commissioner is authorized to charge such fees to Deposit Account 500388 (Order No. CHIRP018R).

Please continue to direct all correspondence to the **correspondence address** indicated below with **Customer Number 27476**.

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP



James E. Austin
Reg. No. 39,489

Correspondence Address:

Customer Number

27476
PATENT TRADEMARK OFFICE

Attorney Young J. Suh
Reg. No. Reg. No. 41,337
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662
Telephone: (510) 923-2706
Facsimile: (510) 655-3542